[
    {
        "header": "Abstract",
        "images": []
    },
    {
        "header": "1Introduction",
        "images": []
    },
    {
        "header": "2Related work",
        "images": []
    },
    {
        "header": "3MADD orchestra",
        "images": [
            {
                "img": "https://arxiv.org/html/2511.08217/x1.png",
                "caption": "Figure 1:Overview of MADD architecture.",
                "position": 362
            },
            {
                "img": "https://arxiv.org/html/2511.08217/x2.png",
                "caption": "Figure 2:Overview of the proposed benchmark",
                "position": 442
            }
        ]
    },
    {
        "header": "4Experimental studies",
        "images": [
            {
                "img": "https://arxiv.org/html/2511.08217/x3.png",
                "caption": "Figure 3:Comparison of drug discovery approaches using average metrics across considered diseases. The filtration groups (GR) are based on molecule properties such as Docking score and IC50 (GR1), SA (GR2), BRENK (GR3), and the latter groups additionally include SurehEMBL, Glaxo, PAINS (GR4), and QED (GR5).",
                "position": 665
            }
        ]
    },
    {
        "header": "5AutoML features of MADD",
        "images": [
            {
                "img": "https://arxiv.org/html/2511.08217/x4.png",
                "caption": "Figure 4:Comparison of F1 score for the MADD automatically created and trained ML pipeline and manually pre-trained models for IC50 predictions.",
                "position": 679
            }
        ]
    },
    {
        "header": "6Case studies",
        "images": [
            {
                "img": "https://arxiv.org/html/2511.08217/x5.png",
                "caption": "Figure 5:Results of case studies: a). Alzheimer’s disease case study; “ChEMBL” - experimentally validated GSK-3β\\betainhibitors from ChEMBL, “MADD” - molecules generated by our approach. b). Thrombocytopenia case study; “SYK-FBRL” - molecules generated by SYK-FBRL approach, “MADD” - molecules generated by our approach.",
                "position": 695
            }
        ]
    },
    {
        "header": "7Discussion",
        "images": []
    },
    {
        "header": "8Conclusion",
        "images": []
    },
    {
        "header": "Acknowledgments",
        "images": []
    },
    {
        "header": "Limitations",
        "images": []
    },
    {
        "header": "Appendix AAppendix",
        "images": []
    },
    {
        "header": "Appendix BAdditional Related Work",
        "images": []
    },
    {
        "header": "Appendix CAdditional Case Studies",
        "images": [
            {
                "img": "https://arxiv.org/html/2511.08217/Images/new/similarity.png",
                "caption": "Figure 6:Tanimoto similarity (maximum values) for all generated molecules",
                "position": 963
            },
            {
                "img": "https://arxiv.org/html/2511.08217/Images/new/dataset.png",
                "caption": "Figure 7:The process of obtaining a validation dataset for an experimental study.",
                "position": 1205
            },
            {
                "img": "https://arxiv.org/html/2511.08217/Images/new/ds_1_new.png",
                "caption": "Figure 8:The correlation matrix between Dataset S queries.",
                "position": 1215
            },
            {
                "img": "https://arxiv.org/html/2511.08217/x6.png",
                "caption": "Figure 9:Comparison of the accuracy (in %) and cost (in USD) of agent pipelines for different models and system prompts.",
                "position": 1337
            },
            {
                "img": "https://arxiv.org/html/2511.08217/Images/new/Transformer_molecule-Encoder.png",
                "caption": "Figure 10:Our CVAE transformer architecture",
                "position": 1687
            },
            {
                "img": "https://arxiv.org/html/2511.08217/Images/new/mtdd-mw.png",
                "caption": "Figure 11:Comparison of the molecular mass of experimentally validated molecules (“Real”) with generated molecules using MTDD-EF and integrated models for: a) Alzheimer’s disease, b) Multiple sclerosis.",
                "position": 1733
            }
        ]
    },
    {
        "header": "Appendix DSupporting information",
        "images": [
            {
                "img": "https://arxiv.org/html/2511.08217/Images/new/diff_architectures.png",
                "caption": "Figure 12:Visualisation of MADD-v2A and MADD-v3 systems.",
                "position": 3173
            },
            {
                "img": "https://arxiv.org/html/2511.08217/x7.png",
                "caption": "Figure 13:Visualisation of MADD-v2C and MADD-v2B systems.",
                "position": 3176
            },
            {
                "img": "https://arxiv.org/html/2511.08217/Images/new/molformer.png",
                "caption": "Figure 14:MolFormer. Schematic representation of the system.",
                "position": 3179
            },
            {
                "img": "https://arxiv.org/html/2511.08217/x8.png",
                "caption": "Figure 15:ChemCrow. Schematic representation of the system.",
                "position": 3182
            },
            {
                "img": "https://arxiv.org/html/2511.08217/Images/new/chemagent.png",
                "caption": "Figure 16:ChemAgent. Schematic representation of the system.",
                "position": 3185
            }
        ]
    },
    {
        "header": "Appendix EAgents prompts and examples of multi-agent system workflow",
        "images": [
            {
                "img": "https://arxiv.org/html/2511.08217/Images/mad_ex2.png",
                "caption": "Figure 17:Question-answer for MADD. The question from Dataset L (hardest)",
                "position": 3584
            },
            {
                "img": "https://arxiv.org/html/2511.08217/Images/mad_ex1.png",
                "caption": "Figure 18:Question - answer for MADD. The question from Dataset M (medium difficulty).",
                "position": 3587
            }
        ]
    },
    {
        "header": "Appendix FLicenses of used artifacts",
        "images": []
    }
]